currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18 F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes "generalist" tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of "specific" tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism.
Introduction

2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG)
is currently the only positron emission tomography (PET) tracer used for routine cancer imaging. Its synthesis was published in 1975 and the first human images were obtained in 1976 [1] . The initial clinical indications were limited to the assessment of myocardial viability and the evaluation of suspected recurrent brain tumours. Thanks to the development of scanners with the capability to rapidly obtain high-quality images, PET has become a major player in the field of oncological imaging.
FDG-PET in oncology relies on research published by Warburg decades ago [2, 3] that showed increased glycolysis in tumour cells, with an increase in glucose metabolism and lactate production and a decrease in oxidative pathways. The simplified mechanism of uptake of FDG by tumour cells is now well understood: as a glucose analogue, FDG enters the cell membrane using the same transporters as glucose (GLUT); it is then phosphorylated into 18 F-FDG-6-phosphate by the hexokinase. This metabolite is not a substrate for further enzymes and thus accumulates inside the cell, in proportion to the metabolism of glucose. Such accumulation of phosphorylated radiotracer creates a gradient between the tumour and surrounding tissues, highly favourable to the detection of cancer lesions.
In tumour cells, along with increased glycolysis, enhanced glucose (and FDG) transport contributes to the intracellular accumulation of the tracer. The increased glycolysis results from two key phenomena: firstly, the loss of the Pasteur effect, i.e. loss of the feedback loop decreasing the ATP production through the inhibition of several key enzymes of glycolysis, and secondly, a reorientation of the pentose pathways towards nucleotide synthesis instead of energy production. An increase in the number of glucose transport molecules (GLUT), in particular GLUT-1, present at the cell surface is responsible for the glucose transport towards tumour cells. The gene coding for GLUT-1, and to a lesser extent the gene for GLUT-3, are overexpressed in cancer cells, in parallel with (not secondary to) overexpression of several protooncogenes involved in cell proliferation. Hence, the overexpression of GLUT-1 stands among the features of malignant transformation, but its relationship with proliferation is only indirect [4] . A thorough discussion of the biological significance of FDG tumour uptake is beyond the scope of this article, but it should be noted that this aspect is far from being fully understood. For instance, the relative contribution of glycolysis and transport varies markedly according to the tumour type. Additionally, many other parameters influence the degree of FDG uptake by cancer cells. Tumour proliferation, hypoxia, fraction of inflammatory infiltrate and even blood glucose level all modify FDG uptake, and their precise contribution remains difficult to evaluate in individual tumours. For instance, FDG uptake is increased in macrophages owing to the inflammatory infiltrate present in both malignant tumours and benign lesions [5] [6] [7] [8] [9] [10] .
Numerous alternative compounds have consequently been proposed, or are being evaluated, for better tumour characterisation. Fluorinated radiotracers appear to be the most attractive option, mainly due to the wide availability of 18 F and the possibility of automated radiosynthesis. Some of these tracers are likely to enter the clinical field of oncology in the very near future. These new compounds can be divided into generalist tracers, i.e. evaluating non-specific aspects of the tumour metabolism, such as protein synthesis, amino acid (AA) transport, nucleic acid synthesis or membrane component synthesis, and specific tracers, dealing for instance with receptors or gene expression.
Fluorinated analogues of amino acids
Amino acid metabolism
Various mechanisms are involved in the production, cell transport and protein incorporation of AAs. There are 20 known AAs, of which nine are called essential AAs, which cannot be synthesised and must be provided by the alimentation. The others can be obtained through intracellular recycling of proteins. AA uptake by the cells may vary according to general parameters such as intracellular concentration of various AAs, pH and temperature. Although AAs may simply diffuse into the cells, their transport principally depends on more than 20 ubiquitous membrane transport systems. Each system is responsible for the transport of one or more AAs. Two groups of transporters are identified: In sodium-dependent systems, the affinity of the catalytic site of the transport protein for the AA is enhanced following the linkage of a sodium ion. These systems depend upon the transmembrane sodium gradient and the membrane potential. They are responsible for transporting large neutral AAs, short side-chain AAs or non-ramified sidechain AAs, including alanine, serine and glycine. The most important sodium-dependent transporters are the systems A, ASC and Gly. The major sodium-independent system is the L-system, but several others exist, such as the systems B 0,+ and y + . These transporters deal with aromatic AAs and ramified side-chain AAs, including leucine, valine, tyrosine and phenylalanine. In sodium-dependent systems, the direction of transport depends on the transmembrane gradient of AA concentration. However, as such a gradient can be created by sodium-independent systems, both transport systems are deeply intricate. Finally, other, non-ubiquitous, systems exist, such as the system T, which transports tyrosine, phenylalanine and tryptophan into the erythrocytes. The majority of these systems are capable of transporting synthetic or non-metabolisable AA analogues.
Once inside the cell, AAs can be incorporated into proteins, through the tRNA and ribosomes. However, they are not merely the building blocks for proteins. They are also precursors for many other biomolecules, such as hormones or neurotransmitters, and enter several metabolic cycles, for instance as methyl group donors. AAs can be degraded into urea, on the one hand, and metabolites transformable into glucose, fatty acids or ketone bodies, on the other hand, thus becoming sources of energy for the cell. Finally, they can also be recycled and utilised by other cells, a process that necessitates transmembrane transport.
Tumour metabolism of amino acids and imaging
Increased transport and/or protein synthesis in tumour cells was demonstrated more than 40 years ago [11] . In vitro, most tumours accumulate one or more AAs [12, 13] , sometimes in competition with other classes of AA [14] . Enhanced transport function may be related to an overexpression of proteins, controlled by oncogenes and proto-oncogenes, especially for the system A [15] . However, it is more probably the simple consequence of higher cell demand for AAs related to increased needs for tumour growth. Hence a simplistic view would relate increased AA transport to sustenance of an increased protein synthesis rate (PSR), both phenomena reflecting the level of tumour proliferation. This view is at best incomplete and partially correct, however, as a significant fraction of the protein synthesis is devoted to maintenance of vital cell functions, independently of proliferation. Furthermore, not all AAs are incorporated into newly formed proteins, as mentioned earlier [16] . Indeed, an increase in AA transport is possible even when protein synthesis is inhibited [17, 18] .
Of the two mechanisms, increased transport and PSR, the former is likely to be the most important as regards PET imaging of tumours using radiolabelled AA analogues [19] . The intratumoural concentration is, however, limited by efflux of the tracer or its labelled metabolites. This phenomenon may be minimised by choosing non-metabolisable compounds, without any efflux of labelled metabolites or with an efflux that is as limited as possible [19] [20] [21] [22] . In addition, these tracers appear to be more specific for tumours than FDG, as the protein metabolism in inflammatory cells appears to be less modified than the glucose metabolism [23] [24] [25] . Nonetheless, several false positive results have been reported with tracers such as [ 11 C-methyl]-methionine (MET) and L-3-[ 123 I]iodo-α-methyltyrosine (IMT), for instance in sarcoid, abscess or angiomas or following irradiation [26, 27] .
The literature classically refers to radiolabelled AA analogues aimed at measuring either membrane transport [26, 27] or PSR [28] . Most early studies and applications were performed using 11 C-labelled compounds, the bestknown being MET. However, the short physical half-life of 11 C prevents its use in most nuclear medicine departments (i.e. those without an on-site cyclotron). Moreover, the physical period is also very short with regard to both protein synthesis, which is a fairly long biological process, and the multiple purification steps required by the radiochemical synthesis. In addition, production costs are very high. Radiolabelling with 18 F has thus generated great interest. Among the numerous 18 Flabelled AAs that are currently being investigated, tyrosine has been under particular scrutiny, especially the following derivatives: 2-
The chemical structure of these compounds is shown in Fig. 1 .
2-[ 18 F]fluoro-L-tyrosine
In the first published F-TYR synthesis, in 1989, an O-acetyltyrosine group underwent an electrophilic fluorination on a triflate (CF 3 CO 2 H) [29] . The specific activity was reported as 10-20 MBq/µmol, with a low radiochemical yield (17%, which is actually obtained from a precursor). More recently, Lemaire et al. proposed a multiplestep procedure using another precursor, 2-trimethylammonium-4-methoxy-benzaldehyde triflate, with a higher yield (25-40% corrected for decay, 100 min) and also higher specific activity [30] .
Tyrosine and probably F-TYR are handled by the L-transport system, which is bidirectional, sodium independent and essentially reliant upon the AA transmembrane gradient [31, 32] . Like its now welldocumented 11 C-labelled counterpart, L-[1-11 C]-tyrosine (TYR), F-TYR was initially proposed as a marker for PSR in tumour cells [29] [30] [31] [32] [33] . In mice, more than 80% of the compound is incorporated into newly formed cerebral proteins 60 min after tracer injection, with a low tRNA-bound fraction and few intracellular radiolabelled metabolites [29] . In humans, F-TYR uptake is significantly higher in primary cerebral tumours than in the normal cortex, with a better contrast obtained soon after tracer injection owing to the rapid rise in the plasma concentration of radiolabelled proteins [31] (Fig. 2) . Further studies suggest, however, that transport is the primary mechanism responsible for the accumulation of F-TYR in tumour cells. Compartmental modelling applied to 15 patients with gliomas showed that K 1 is the most increased parameter in tumours as compared with normal tissues [31] . Ishiwata et al. systematically compared F-TYR, L-[ 3 H]methyl-methionine and L-1-[ 14 C]leucine ( 14 C-LEU) in tumour-bearing mice [34] . Although protein incorporation was high using all three tracers, The lesion is seen as a focus of decreased activity, as compared with the cortex, on the FDG scan, and as a focus of increased activity on the F-TYR study 14 C-LEU showed the faster PSR. Moreover, cyclohexomidine, which is a selective inhibitor of protein synthesis, decreases 14 C-LEU uptake but not F-TYR uptake, whereas transport blockade with ouabain decreases the uptake of all three tracers [17] . A recent clinical study reported somewhat disappointing results in terms of the sensitivity of F-TYR for detection of tumour lesions of various types, but interestingly enough there was a wide disparity between the levels of uptake of both FDG and F-TYR in some of the lymphoma patients, which may suggest prognostic implications [35] .
L-3-[ 18 F]fluoro-α-methyl tyrosine
FMT was first proposed in 1997 [36] . The radiosynthesis is based on non-specific radiofluorination with acetylhypofluorite; its specific activity and yields are very low. It accumulates more rapidly and intensely than FDG in animal tumour models [37, 38] . FMT uptake relies essentially upon the large AA transport systems. Like the 123 I-labelled IMT, its incorporation into proteins is very limited [38, 39] . The affinity for the transporters is, however, different for FMT and for α-methyl derivatives [40] [41] [42] . Watanabe et al. compared FMT and FDG in a series of 75 patients with musculoskeletal tumours [43] . The tracers showed the same sensitivity (73%), but FMT was significantly more specific than FDG (85% vs 66%). FMT performed better in distinguishing benign lesions from malignant tumours, whereas FDG was more accurate for grading the tumour lesions. Nevertheless, the sensitivity of FDG-PET was low in this study, and lower than that reported in most other studies, where it is consistently higher than 90% [44, 45] . The same group compared FMT and FDG in 19 patients with suspected or demonstrated malignancies and found 91% sensitivity for FDG as compared with 74% for FMT [46] . Larger studies are thus needed to establish whether FMT (and other AA analogues) can demonstrate sensitivity as high as FDG, while improving its specificity for cancer.
O-(2-[ 18 F]fluoroethyl)-L-tyrosine
Like FMT and IMT, FET is a tracer of AA transport, without significant incorporation into newly formed proteins [47, 48] . The synthesis, which was developed in 1999 by Wester et al. [47] is fairly simple and straightforward. It is completed in no more than 1 h, with high radiochemical yields (40%) and specific activity. Tumour uptake is rapid, and no radiolabelled metabolites are detected in the blood up to 1 h after injection [49] . One major advantage of this tracer is that it appears highly specific for cancer. Rau et al. [50] compared the uptake of three tracers (FDG, MET and FET) in various animal models, including tumour, acute inflammation (lymphadenitis caused by concanavalin A) and chronic inflammation (streptozotocin-induced lymphadenitis). Whereas all three lesion types were highly avid for FDG and MET, only the tumours showed increased FET uptake as compared with controls. Few data exist in patients, however. Preliminary results in seven patients with disseminated melanomas suggest complementarities between FDG and FET, with some of the lesions negative with FET being positive with FDG and vice versa [51] . Another study in 16 brain tumour patients reported encouraging results, as all lesions were clearly seen with a high contrast and good correlation with MET uptake [52] .
Dihydroxyphenylalanine (DOPA) is a tyrosine metabolite. It has been labelled with 18 F in the position 2 (2-FDOPA [53] ) or 6 of the aromatic ring (6-18 F-L-3,4-fluorodihydroxyphenylalanine, 6-FDOPA [54] ). As the yield is higher, and the synthesis process much simpler, with 6-FDOPA than with 2-FDOPA, only the former is in fact currently utilised. Large amounts of 6-FDOPA can be produced using a multistep reaction based on a nucleophilic substitution of an aromatic aldehyde. Alkylation of protected glycine with radioactive benzyl bromide under phase transfer catalysis followed by an acidic deprotection gives 6-FOPA (C. Lemaire, personal communication). Both compounds use the L AA transport system to enter the cells. Uptake quantitation is hampered by the presence of circulating radiometabolites (O-methyl-FDOPA), which may in turn re-enter the cells via the same transport system. 6-FDOPA is currently used to investigate the brain dopaminergic system in various movement disorders. Both the decarboxylation of the compound and the release into blood of radiometabolites can be reduced with carbidopa, a decarboxylase inhibitor.
In oncology, FDOPA has been proposed as a biomarker for melanomas. In an animal model, 2-FDOPA accumulated in melanomas and breast tumours, but the uptake was significantly higher in tumours with a high level of melanin synthesis [55, 56] . However, DimitrakopoulouStrauss et al. clearly showed in melanoma patients that 6-FDOPA uptake is not related with melanogenesis, but rather depends on transport [57] . 6-FDOPA may therefore be envisaged as an oncological radiotracer, potentially complementary to FDG [58] . Recently, Hoegerle et al. have reported very encouraging results in infrequent tumours such as carcinoids, medullary thyroid carcinomas, phaeochromocytomas and glomus tumours [59, 60] . It appears that the most accurate diagnosis is achieved using combinations of FDOPA and conventional methods, or FDOPA, FDG and conventional methods. FDOPA was also recently proposed as an alternative to MET for evaluation of primary brain tumours, the lesion/cortex activity ratios being very similar for the two compounds [61] . The sensitivity remains an issue, however, as reported in a series of patients with small cell lung cancer [62] . Indeed, the tumour to background contrast is generally lower with FDOPA than with FDG, as shown in Fig. 3 .
Somatostatin receptor imaging with fluorinated compounds: [ 18 F]fluoro-octreotide
Somatostatin (SST) is a cyclic peptide whose two active forms consist of 14 and 28 AAs (SST14 and SST28). It is secreted in the brain (in particular but not exclusively in the hypothalamus), the digestive tract (D cells) and the thyroid (C cells). SST displays locoregional inhibitory hormonal properties on both the physiological and the tumour-related synthesis of growth hormone, insulin, glucagon and gastrin, as well as antiproliferative features, through modulation of the immune response and inhibition of angiogenesis. SST acts on tissues expressing membrane receptors (SSTRs), which consist of five different polypeptides (SSTR 1-5). All SSTR subtypes are activated trough the G protein system, but the endeffect of SST depends on the receptor subtype and the target tissue. SSTRs have been found in a wide variety of tumours, in particular neuroendocrine tumours, which mostly derive from the APUD system cells (amine precursor uptake and decarboxylation), but also brain, thyroid (medullary), lung cancers (small cell) and lymphomas, among many others [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . Various nonmalignant diseases also show significant levels of SSTR expression, such as Graves' disease, rheumatoid arthritis and sarcoid [64] .
Octreotide is an SST analogue with a longer biological half-life. It is metabolised in the liver. Hormonal properties of octreotide are close to those of SST in that it binds to the SRIF1-class SSRT (SRIF: somatotropin release inhibiting factor), which includes the SSTR2, SSTR3 and SSTR5 subtypes. Whereas the two active forms of SST have a similar affinity for all receptor subtypes, octreotide affinity is highest for SSTR2, and it does not bind significantly to the SRIF2-class SSRT (SSTR1 and SSTR4) [64, 76] .
Octreotide is indicated for treatment of neuroendocrine tumours such as carcinoids, VIPomas and glucagonomas, with an efficacy that is directly correlated with the level of SSRT expression in the tumour [77] . Radiolabelled SST analogues may thus be used for both diagnosis and therapy planning. Such analogues include 123 I-Tyr 3 -octreotide [78] , 111 In-DTPA-D-Phe 1 -octreotide ( 111 In-pentetreotide) [79] and the newer technetium-99m-labelled compounds [ 99m Tc]-N 4 -Bz-octreotide [80] and [ 99m Tc]-PnAO-D-Phe 1 -octreotide [81, 82] . 111 In-pentetreotide is the only radiopharmaceutical routinely used in clinical practice, mainly for diagnosis, staging or followup of gastro-entero-pancreatic neuroendocrine tumours [83] . Several PET tracers are currently being investigated, mainly as dosimetric surrogates for beta-emitter compounds developed for therapy [84] [85] [86] [87] .
The first fluorinated octreotide analogue, 2-[ 18 F]fluoropropionyl-D-Phe 1 -octreotide [88] (Fig. 4) , showed very poor biodistribution properties in rats, with low tumour uptake and high accumulation in the liver [89] . Recent studies demonstrate that conjugating analogues with carbohydrates improves the biodistribution, with decreased uptake by the fatty tissue, liver and plasma proteins, in- creased tumour uptake and renal excretion [90, 91] . Synthesis of the first carbohydrated derivative labelled with 18 
was very recently reported by Wester et al. (Fig. 4) . The synthesis is achieved within 3 h, with radiochemical yields in the 30-40% range [92] . In rats, Wester et al. found that the tracer was rapidly excreted via the kidneys, with limited liver and bowel uptake and very high tumour accumulation (pancreatic carcinoma). In the same article, the authors reported on the first human study with [ 18 F]FP-Gluc-TOCA in a patient with liver metastases from a carcinoid tumour. All the known lesions were clearly visualised, with standardised uptake values (SUVs) ranging from 21 to 38, and an additional abdominal lesion was revealed. These results are encouraging but further studies are of course needed to assess the clinical performance of the tracer as well as its possible role as compared with other positron-emitting radiopharmaceuticals.
Fluorinated nucleosides
The level of proliferation is obviously a key parameter when it comes to characterisation of neoplastic lesions. The relationship between FDG uptake and proliferation is highly complex. Protein synthesis, as measured using radiolabelled AA analogues, only imperfectly and indirectly reflects cell proliferation. DNA synthesis is the process that is most reliably associated with proliferation. The effectiveness of tritiated thymidine in measuring DNA synthesis has been well documented, and it is indeed widely employed in in vitro studies. Thymidine has also been successfully labelled with 11 C, and the tracer uptake is directly related to cell proliferation. However, use of 11 C-thymidine is hampered by the short isotope half-life, the difficult radiosynthesis and the presence of circulating radiolabelled metabolites. Several alternative compounds, labelled with 18 F, have thus been proposed, including 3′-deoxy-3′-
FBAU, FMAU and FAU are, unlike FLT, incorporated into DNA. These tracers are still at a very early stage of development, and few data are available regarding their potential for whole-body imaging. We shall therefore concentrate our further discussion on FLT, which is increasingly well documented.
Radiosynthesis of 3′-fluoro-3′-deoxythymidine
Unlabelled 3′-fluoro-3′-deoxythymidine has been recognised as an antiviral agent for more than 10 years [93] .
The synthesis of FLT was first reported in 1991, but the low radiochemical yield prevented routine clinical use of the compound [94] . Since then, various precursors have been proposed, using various synthesis pathways. [95, 96] but the filtration of precipitate salts limits the possibility of developing automated production. Other obstacles arise when using another precursor, 5′-O-(4,4′-dimethoxytrityl)-2,3′-anhydrothymidine [97, 98] , such as the high temperature for labelling, the low radiochemical yield and the use of non-volatile DMSO, which can interfere during the high-performance liquid chromatography (HPLC) purification. Currently, 3-N- [99, 100] appears to be the precursor of choice. The procedure is fairly simple, with a one-step hydrolysis in a homogeneous solution, without any filtration. The radiochemical yield is about 12% EOB (end of bombardment) and radiosynthesis time is 85 min. (hydrolysis 45 min and HPLC 40 min). Furthermore, this process could easily be transposed and adapted to an FDG synthesiser. Figure 5 shows the chemical structure of FLT.
Metabolism of FLT
Nucleosides, including FLT, enter the cells by facilitated diffusion and by a carrier-mediated mechanism. Two types of transport molecule, es and ei, control the influx and efflux of nucleosides. FLT is a substrate for the es system [101] . Once inside the cell, nucleosides are phosphorylated. Although four kinases are involved in the nucleoside metabolism, FLT is only handled by thymidine kinase TK1 and to a much lesser extent by TK2. The activity of the cytosolic isoenzyme TK1 is cell cycle dependent [102] [103] [104] [105] . TK1 is genetically coded and its expression is controlled by the transcriptional factor E2F, which belongs to signal pathways regulating cell proliferation (retinoblastoma protein pathway, pRb) [106] [107] [108] [109] [110] . TK1 expression is strictly controlled in normal cells and is only enhanced in the late G 1 phase and the S phase. It is much higher, by up to 15-fold, in tumour cells, in which TK1 expression is also uncoupled from the DNA synthesis [111, 112, 113] . Moreover, oncogenes may be activated through the pRb pathways, leading to E2F factor deregulation and abnormal TK1 expression [108, 109] . TK1 overexpression is thus frequently observed in proliferating tumour cells.
FLT uptake and cell proliferation
TK1 has a high affinity for FLT, albeit lower than for thymidine. Toyohara et al. [114] The measurement of cell proliferation using [ 3 H]TdR relies on its accumulation both after phosphorylation by TK1 and after incorporation into DNA during replication. The monophosphorylated form of FLT (FLTMP) similarly accumulates inside the cells but there is no further phosphorylation to triphosphate derivatives. Some studies reported no incorporation of FLT into DNA [115] [116] [117] [118] but recently the group in Ulm showed a significant in vitro incorporation in lymphoma and pancreatic cancer cell lines [119, 120] . Such conflicting results may be related to the experimental setting, and in any case all data confirm a clear relationship between FLT uptake, TK1 activity and proliferation in tumour cells. FLTMP can be hydrolysed into FLT by the 5′-nucleotidase (5′-NT) and consequently leak out of the cells. This leakage is, however, merely potential; as it competes with high levels of phosphorylation by TK1, it is only responsible for a very limited reduction in intracellular accumulation of the compound [101] .
Human studies reveal high bone marrow uptake of FLT, as well as significant liver and urinary tract distribution. The tracer is indeed glucuronidated in the liver before being excreted by the kidneys. Unlike FDG, FLT is not taken up by the normal cortex, which is clearly an advantage for evaluation of brain tumours. The radiation dosimetry of FLT in human PET studies was recently published and shows dose estimates compatible with routine clinical use (the [ 18 F]FLT effective dose equivalent (mean ± SD) was 0.028±0.012 mSv/MBq for a standard male patient and 0.033±0.012 mSv/MBq for a standard female patient) [121] .
Several clinical evaluations are now available for various cancer types in patients. Buck et al. [122] showed an excellent correlation between FLT uptake, as measured using the SUV, and the proliferative activity of 22 malignant lung tumours, as measured using Ki-67 immunostaining. Furthermore, there was no significant FLT uptake in any of the eight benign lesions, and the sensitivity was 86%, using visual interpretation. The same group further compared FLT and FDG in patients with various lung lesions and found that FLT has a better correlation with proliferative index, a higher specificity (no false positive results vs 4/8) and a slightly lower sensitivity (three false negative results vs one) than FDG [123] . Dittmann et al. studied 16 patients with various tumours and found a high sensitivity for FLT, although the uptake intensity was lower than with FDG [124] . Due to the high physiological uptake in the liver and the bone marrow, sensitivity may be limited for detection of metastases in these organs. This is emphasised by Francis et al., who studied patients with colorectal cancers with both FLT and FDG [125, 126] . Although the primary tumours and lung and peritoneal metastases were well visualised, FLT missed the majority of the liver lesions (sensitivity 34%).
These results indicate that FLT-PET is a potentially useful tool for diagnosis and staging, but its major impact should stem from its capability to evaluate early on the response to treatment. Barthel et al. reported good correlations between changes in FLT uptake and both the proliferative activity (by PCNA labelling) and the tumour volume changes in mice treated with the antiproliferative drug 5-FU [127] . Although FDG uptake also decreased after treatment, these changes were less pronounced than with FLT. This issue remains to be carefully examined, as Dittmann et al. conversely reported an increased FLT uptake early on following incubation of cells derived from human squamous cell carcinoma with 5-FU and methotrexate [128] . This is explained by the well-known induction of salvage pathways of DNA synthesis. Using another drug, cisplatin, the authors observed a rapid decrease in FLT uptake, which indicates that FLT needs to be carefully and systematically evaluated in various experimental models before FLT-PET is considered a valid method for assessing the response to treatment.
The specificity of the tracer is another aspect that needs further validation, as a false positive result has been reported in a sarcoid lesion [129] . Initial patient studies are, however, very encouraging, and animal experiments similarly show very limited FLT uptake in an E. coli infectious model [130] .
In summary, there is tremendous interest in FLT among the nuclear medicine community, and validation of the tracer is well underway. Although several important issues remain unanswered, this tracer is clearly among the most promising developments for PET imaging.
Fluorinated analogues of membrane phospholipids: choline analogues
Membrane lipid metabolism
Membrane lipids can be grouped into two classes: phospholipids, with the diacylphosphoglycerides and the sphingolipids, on the one hand, and cholesterol, which is the only sterol present in cytoplasmic membrane, on the other hand. Phospholipids contain a polar group (substituted phosphoglycerol) and an apolar group (hy-drocarbonated chain). The diacylphosphoglycerides derive from the esterification of glycerol by a phosphoric acid derivative, for instance phosphatidylcholine, which is the most frequently encountered in the membrane. The main constituent of sphingolipids is ceramide, a precursor for sphingophospholipids and sphingoglycolipids. Sphingomyelin, whose phosphated derivative is also phosphatidylcholine, is the most abundant sphingolipid in mammal's plasmic membranes.
Choline is a quaternary ammonium base. Even though choline is partly synthesised de novo, it also has to be found in the alimentation and it thus received the status of vitamin (group B) in 1998 from the US Food and Nutrition Board of the Institute of Medicine. It crosses the blood-brain barrier, protects the nerves' myelin sheath and is a precursor for acetylcholine. Choline therefore plays a primary role in the development and function of the brain. It is also one of the fundamental constituents of membrane phospholipids and contributes to the circulation of fatty acids and cholesterol through these membranes.
Choline enters the cell using specific transporters, both sodium dependent and sodium independent. The sodium-dependent system has a high affinity for choline (HACU, high-affinity choline uptake) and is located in the presynaptic nerve endings (acetylcholine synthesis). The sodium-independent system has a low affinity for choline; it is expressed in most cells and participates in the transport and intracellular concentration of choline, which is then rapidly phosphorylated into phosphatidylcholine (whose intermediary metabolites are phosphorylcholine and cytidine-diphosphate-choline) or oxidated into betaine in the liver and kidneys. The first metabolite, phosphorylcholine, which results from the intervention of a choline kinase, remains trapped inside the cell.
The cell malignant transformation is associated with enhanced activity of the choline kinase, which is itself related to tumour proliferation and increased need for cytoplasmic membrane constituents, in particular phosphorylcholine and phosphatidylcholine [131, 132] . De novo choline synthesis is slow in tumour cells, so that the increased uptake of radiolabelled choline may reflect the cell duplication rate [133] .
Fluorinated choline analogues
Hara et al. pioneered the use of 11 C-choline in man, which is now well documented [134] . Several tumours have been studied, including brain [135] , lung [136] , oesophagus [137] , colon [134] and prostate [138] . In 1997, the same team proposed the automated synthesis of a fluorinated choline analogue, 2-[ 18 F]fluoroethyl-dimethyl-2-oxyethyl-ammonium ( 18 F-fluoro-ethylcholine, FEC) [139] . However, this process is hampered by the necessity of eliminating Kryptofix 2.2.2, a catalyser that is toxic and cannot be administered to humans. To address this The radiochemical purity is higher than 99% (HPLC) [142] and the yield is approximately 30-40%, with a specific activity ranging from 37 to 185 MBq/µmol [141] . The radiolabelled compound remains highly stable after 2-h incubation in blood samples. Phosphorylation rates were found to be similar for choline and its fluorinated analogue (FCH), which indicates that in vitro, FCH is also a substrate for the choline kinase [141] . It was shown in the same study that the uptake of choline and FCH was similar in human prostate cancer cells (PC-3), and that inhibition of transport and phosphorylation using a specific inhibitor (hemicholinium-3, HC-3) decreased the uptake of FCH and choline by 89% and 45%, respectively. The majority of FCH is actually retrieved in PC-3 cells as a phosphorylated metabolite (phosphoryl-fluorocholine), and there is no fluorinated derivative of betaine, which demonstrates the absence of significant oxidation of FCH.
The biodistribution of both 18 F-fluorocholine and 18 Ffluoro-ethylcholine is very similar to that of choline, except for their very rapid urinary excretion [143] . Preliminary human studies are very encouraging, especially in the field of prostate cancer [144, 145] . Price et al. found that the FCH uptake was up to four times higher than FDG uptake in 18 patients with prostate cancer, whether androgen independent or androgen dependent (nine patients in each group) [145] . FCH detected more primary tumours and metastases, including to the skeleton, as compared to FDG. In another series of 16 patients with prostate carcinoma, Hara et al. found a similar level of uptake for FEC and 11 C-choline, but the spatial resolution of FEC imaging was slightly superior owing to the shorter positron range for 18 F as compared to 11 C [144] . It should be noted that these excellent results were obtained using bladder catheterisation to allow better visualisation of the prostate area.
DeGrado et al. also synthesised two other choline analogues [141] : [ 18 F]fluoropropyl-dimethyl-2-hydroxyethylammonium ( 18 F-fluoropropylcholine; FPC) and [ 18 F]fluoromethyl-methylethyl-2-hydroxyethylammonium ( 18 F-fluoromethyl(ethyl)choline, FMEC). In in vitro experiments with the aforementioned PC-3 cell line, FMEC uptake was significantly lower (by approximately 50%) than that of FCH and FPC. Conversely, the phosphorylation rate of FCH was twice as high as that of FPC. As pointed out by Hara et al. in an accompanying editorial, these results may have been influenced by potential contamination by dimethylethanolamine [133] . This compound, which is used during the synthesis according to DeGrado et al., is also an inhibitor of choline uptake by tumour cells both in vitro [146] and in vivo [147] . Such contamination was not sought in this study, and the properties of these two radiotracers should thus be further investigated.
In addition, little is known regarding the specificity of these tracers. Recently, Wyss et al. reported very high 18 F-fluorocholine uptake in an animal model of infection, which may limit its usefulness in routine imaging [148] . Nevertheless, given the high prevalence of prostate cancer and the absence of any satisfying PET tracer thus far, fluorinated choline analogues may well turn out to represent a major advance in the work-up of these tumours. The chemical structure of choline and fluorinated choline analogues is shown in Fig. 6 .
Fluorinated analogues of sexual steroids
Sexual steroids act on sexual functions and determine the secondary sexual characteristics. Among the gonadal sexual steroids, oestrogens derive from the oestrane nucleus, progestins from the pregnane skeleton and androgens from the androstane skeleton. These hormones are synthesised in the gonads (testes and ovaries), adrenals, placenta and central nervous system (neurosteroids). Their secretion is controlled by the hypothalamic-hypophyseal axis. Gonadal synthetic pathways start with cholesterol being delivered to the cells by the plasma lipoproteins. The hormones are glucuronoconjugated in the liver and further eliminated by the kidneys.
Fluorinated oestradiol derivatives
Oestrogens play a major role in the development of breast cancer, as shown by epidemiological data and experimental findings concerning, for example, their mitogenic effect on established breast cancer cell lines or their capacity to induce breast cancer in animal models. Endocrine approaches, in particular using tamoxifen, are thus an important tool in the treatment of breast cancer. However, 30-40% of all breast cancers do not express oestrogen receptors (ER−), and of the tumours with oestrogen receptors (ER+), up to 50% will not respond to endocrine treatment. Conversely, 10% of ER− tumours will respond to such treatment. The ER status is assessed using immunohistochemistry analysis of tumour samples. It is believed that a non-invasive method which would accurately evaluate and quantify the presence of ER on the tumour and its metastases could better select patients for treatment and predict the therapeutic response. More than 20 fluorinated oestrogen derivatives have been proposed for this purpose.
Among [150] . The affinity of the tracer for SBG is an important parameter, because oestradiol and its derivatives are transported in the bloodstream bound either to SBG or to albumin. SBG binding protects steroids against liver metabolism and ensures their transport to the target tissues. Moreover, their affinity for SBG also contributes to their cell uptake, through membrane receptors for SBG [151] [152] [153] .
Other molecules are still at the preclinical level of development. This applies, for instance, to the difluoroestradiols, in which a second fluoride-18 is added in position 2 or 4 of the FES molecule to improve the in vivo stability. However, the affinity for SBG is decreased in the process. The most promising compound in this class appears to be 4,16-[16α- 18 F]difluoro-11β-methoxyoestradiol, whose uptake by the uterus in immature female rats is higher than the [ 18 F]FES uptake [154] . This tracer has yet to be clinically evaluated, however.
The synthesis of [ 18 F]FES using trifluoromethane sulphonate precursors (triflates) was first published in 1984 [149] . An alternative procedure, faster and more robust, used another cyclic sulphone as a precursor. This procedure was then automated, with an average radiochemical yield of 50%, an 80-180 GBq/micromole specific activity and a total duration of 50 min [155] . In rats and humans, about 95% of [ 18 F]FES is bound to plasma proteins (either SBG or albumin) [156, 157] . The non-specific binding rate to albumin is comparable to that of oestradiol, but the affinity to SBG is tenfold lower [158, 159] . Even though most [ 18 F]FES initially binds to albumin immediately after intravenous administration, very quickly thereafter (within less than 20 s) the tracer is transferred to SBG [158] . At equilibrium, 45% of the non-metabolised [ 18 F]FES is bound to plasma SBG, and this fraction remains stable over time, which theoretically would allow delivery of a sufficient amount of tracer to image ER+ tissues. Furthermore, [ 18 F]FES has high affinity to ERs [149, [160] [161] [162] , which is, of course, indispensable for such a highly specific imaging method. However, other factors must be taken into account, as demonstrated by Mathias et al. in a mammary tumour model in rats [156] . These investigators found that the uptake of [ 18 F]FES in ER+ tissues (uterine and mammary tumours) peaked early, less than 1 h after injection, with a slow decrease subsequently. However, ER+ tissues/ER− tissue activity ratios were only slightly positive immediately after tracer injection, and progressively increased over time to reach a maximum after 2-3 h. This study suggested that parameters such as blood flow, binding kinetics, retention and wash-out of [ 18 F]FES also intervene in the extent of the tracer gradient between ER+ tissues and ER− tissues, especially in small tumours. Moreover, the rapid in vivo metabolism of In human studies, [ 18 F]FES has been used in breast cancer for the detection and staging of disease [161, 163] , prediction of the response to treatment [164] and demonstration of the anti-oestrogenic effect of tamoxifen [165] . Dehdashti F]FES and PET (sensitivity 93%), and the uptake had significantly decreased when measured an average of 17 days after initiating the antioestrogen treatment (tamoxifen or toremifen) [163] . A "metabolic flare" is sometimes observed and usually followed by clinical remission, but this may be confused with progressive disease, which would require salvage chemotherapy. Dehdashti et al. hypothesised that such metabolic changes associated with an agonist effect could be evidenced using a combination of FDG and [ 18 F]FES PET imaging [165] . Indeed, in a small series (11 postmenopausal patients with biopsy-proven ER+ metastatic breast cancer), [ 18 F]FES-PET and FDG-PET performed before and 7-10 days after initiation of tamoxifen treatment showed increased FDG uptake ("metabolic flare") and decreased FES uptake in the seven responding patients. In non-responding patients, FDG uptake did not change after treatment, [ 18 F]FES uptake was lower on the baseline study than in responders, and the post-treatment decrease in [ 18 F]FES uptake was also more limited.
Fluorinated tracers of oestrogen sulphatase inhibitors: [ 18 F]fluoro-disulphamates
Oestrogen sulphates are an important source of oestrogens for hormone-sensitive breast tumours. They are hydrolysed 
Fluorinated androgen analogues
Fluorinated androgen analogues have been proposed for imaging of tumours expressing androgen receptors (AR), in particular prostate cancer. The concept is very similar to the radiolabelled oestrogen analogues for breast cancer imaging. Prostate growth and differentiation is regulated by testosterone derivatives, i.e. dihydrotestosterone, androstenedione and 5α-androstenedione. In prostate tumours, AR-expressing cells coexist with AR-negative cells, and there is a correlation between the level of AR expression in tumours and their response to hormone treatment [181] [182] [183] [184] , although the relationship between AR expression and overall prognosis is unclear [185] . [152, 181] all showed a satisfactory affinity for AR and good in vivo targeting in rats. The compounds labelled in position 16β were rapidly defluorinated, however, resulting in high bone uptake and lower tumour uptake than with other derivatives [152] . Moreover, maximum plasma tracer concentration was reached too late to warrant consideration for clinical use.
Androgen analogues must combine a high affinity for SBG (for the same reasons as explained in the section on ER ligands) and a low affinity for PR, which are also expressed in some prostate tumours. It should be noted that SBG is present in all primates but not in mature rats, which may complicate the evaluation of these tracers [158] . 16β-[ 18 F]FDHT has a high affinity for both AR and SBG [152, 186] whereas the affinity of mibolerone derivatives is high for ARs and low for PRs [181] . In baboons, Welch's group showed much higher prostate uptake with 16β-[ 18 F]FDHT than with 16β-[ 18 F]Fmib and 20-[ 18 F]Fmib, whose affinity for SBG is low [187] . The same investigators demonstrated the protective role of SBG against the metabolisation of AR fluorinated ligands [188] .
As an alternative, fluorinated derivatives of dihydrotestoterone labelled in position 7 were recently developed, including 7α-[ 18 F]fluoro-17α-methyl-5α-dihydrotestosterone ([ 18 F]MDHT) [189, 190] . Labaree et al. showed that these fluorinated steroids have a high affinity for androgen receptors, in fact significantly higher than their iodinated counterparts. The most promising compound is [ 18 F]MDHT because of its high affinity and biological activity in vitro as well as its high stability in aqueous medium at 37°C (whereas the iodinated ana-in tumours by an oestrogen sulphatase. Control over this enzyme activity, using sulphatase inhibitors (e.g. sulphamates), could lead to therapeutic improvements. Oestradiol disulphamate is among the most potent sulphamates.
The [155, 167] . The synthesis is fast, about 1 h (+30 min for quality controls), with 11-15% radiochemical yields (20-25% corrected for decay), and the specific activity may reach 400-500 GBq/µmol.
In rats, Rodig et al. demonstrated a good correlation between [ 18 F]FESDS uptake, oestrone sulphatase (ES) mRNA expression and ES enzymatic activity [168] . Biodistribution studies have been performed in various rodent models. In rats, the high blood concentration of the tracer suggested a significant reaction with another enzyme, carbon anhydrase (CA). Similarly, there was high uptake in organs with high CA activity, such as the spleen, heart, lungs and bone marrow [169] . Administering acetazolamide (an inhibitor of CA) decreased [ 18 F]FESDS uptake by these organs, which confirmed the hypothesis. In mice, tumour uptake was highest in tumours with the highest CA activity, and it also decreased after administration of acetazolamide. Imaging and dynamic studies performed in pigs were rather disappointing, as only the bladder and the brain were seen on the images. Measurements on blood samples also showed high concentrations of the tracer. These preliminary studies, showing a higher affinity of [ 18 F]FESDS for CA than for ES, obviously reduce the potential clinical use of the tracer. To date, there have been no reports of human studies using this compound. [171, 172] showed high affinity for progesterone receptors in rodents [170, [172] [173] [174] . Human studies could not find any clinical role for these molecules, however. Indeed, rapid metabolism, high background activity and poor correlations between [ 18 F]FENP uptake and progesterone receptor (PR) density in tumours all limited the potential applications in breast cancer imaging [175, 176] . Further efforts to develop alternative compounds, such as 6α-[ 18 F]fluoroprogesterone, labelled in position 6, failed for similar reasons [177] .
Fluorinated progesterone receptor ligands
Finally, another family of tracers includes the 16α, 17α-dioxolanes, labelled in position 4 [178, 179] or 21 [180] . They all show high affinity for PR, and favourable biodistribution in rodents, but none has yet been clinically evaluated in humans [178] [179] [180] .
logue is rapidly metabolised) [189] . Prostate targeting was excellent in mature rats, with peak uptake reached as early as 1 h post injection and a slow decrease after 2 h [190] . These encouraging results remain to be confirmed in human studies, which may prove difficult as [ 18 F]MDHT could be rapidly metabolised, owing to its low affinity for SBG [190] . To date, none of these fluorinated androgen analogues has been clinically evaluated. Figure 9 shows the chemical structures of various fluorinated analogues of steroids.
Fluorinated tracers for assessing hypoxia
Cell hypoxia and resistance to treatment
The role of oxygen concentration in the tumour response to irradiation has been known for a very long time. It is established that hypoxia to some extent protects tumour cells against irradiation and various chemotherapy agents such as mitomycin C and porfiromycin. Hypoxia induces the transcription of factor 1α, which leads to the expression of genes that contribute to the cell adaptative response to hypoxia [191, 192] . This response includes an increase in the tumour vascularisation, resulting from the production of the vascular endothelium growth factor (VEGF) [193] . In parallel, there is a selection of cells with mutated p53 gene, which leads to blocking of apoptosis pathways and to a genetic instability favouring the amplification of genes involved in the chemotherapy drug resistance [194] [195] [196] . These mechanisms result in an increased survival and proliferation potential for tumour cells. As such, hypoxia could be an important factor enhancing or triggering the resistance to treatment, particularly radiation therapy in numerous solid tumours. Several studies have shown a negative correlation between the hypoxic fraction and the response to irradiation in gliomas, cervical carcinomas, head and neck cancers and soft tissue sarcomas [192, [197] [198] [199] [200] . Hypoxic cells can be found in virtually all solid tumours, but in numbers that vary with time and the pathological type [201] . Moreover, the proportion of hypoxic cells varies significantly for a given tumour, independently of its clinical or radiological presentation [202, 203] .
Assessment of tumour hypoxia and physiological bases of hypoxia tracers
A method that could reliably, reproducibly and non-invasively measure the tumour hypoxic fraction would expedite the development of new therapeutic strategies specifically targeted against hypoxic cells. Moreover, it would be highly valuable as a pre-treatment prognostic indicator.
Currently the only available method relies on the use of Eppendorf needle measurement of oxygen partial pressure (pO 2 ) [204, 205] . Clinical studies using this technique showed significant correlations between pO 2 and response to treatment [192, 198, 206] . However, the Fig. 9 . Fluorinated analogues of steroids method has several limitations: it can only investigate superficial lesions and it cannot be routinely applied due to its invasiveness and practical considerations. For similar reasons, repeated measurements are difficult to obtain [206, 207] . Moreover, it cannot distinguish necrosis areas from anoxic but viable cells [208] .
The sustained interest in the scientific literature in the development of non-invasive methods is therefore not surprising. Among these, radiolabelled nitroimidazole derivatives have generated a large amount of data. 2-Nitro-1H-imidazole (azomycin) was developed in the 1950s as an antibiotic targeted against anaerobic germs. Chapman et al. were the first to propose nitroimidazoles as bioreducible markers of hypoxia [209] and as a sensitising factor for radiation therapy of hypoxic tumours [210] . Nitroimidazoles are, in a hypoxic medium, reduced into reactive intermediary metabolites by intracellular reductases. This process is directly related to the hypoxia level, with production ratios of the reduced metabolites that can reach 40 times those observed in normoxic cells [211, 212] . This phenomenon obviously creates a gradient highly favourable for specific detection of hypoxic cells [213] . Furthermore, these metabolites covalently bind to thiol groups of intracellular proteins and therefore accumulate within viable hypoxic cells [213, 214] . These complexes can be detected using various techniques, including monoclonal or polyclonal antibodies, magnetic resonance spectrometry, flow cytometry, autoradiography and scintigraphy, when the nitroimidazoles are radiolabelled [215] [216] [217] [218] [219] [220] [221] .
Radiolabelled misonidazole analogues
2-Nitroimidazole can be labelled with fluorine-18, iodine-123 and iodine-131 (iodinated azomycin arabinoside or IAZA), and technetium-99m. Among these, [ 18 F]fluoromisonidazole (FMISO) [222] [223] [224] and IAZA [209, 225, 226] are the most extensively studied, with PET and SPECT, respectively. [228] . This method produces [ 18 F]FMISO with high purity (>99%), high yield (40% EOB) and a 37 TBq/mmol specific activity. A simplified, 50-min single-step synthesis has also been proposed:
is produced with even higher yield (55-80%) [229, 230] . However, the precursor's synthesis is longer (five steps) than with Grierson's method.
Preliminary studies with tritiated and fluorinated derivatives of FMISO were performed at Washington University in Seattle from 1987 to 1990. The first paper reported comparable uptake levels for [ 3 H]FMISO and [ 3 H]misonidazole in vitro using hypoxic V-79 cells and in vivo using tumour-bearing mice [218] . The second article evaluated [ 18 F]FMISO uptake in various tumour cell lines (V-79, EMT-6, RIF-1 and canine osteosarcoma) incubated under hypoxic conditions. The uptake ratio between hypoxic and normoxic cultures ranged from 12 to 27, depending on the tumour type. These experiments established in vitro the good selectivity of [ 18 F]FMISO for hypoxic cells. Using various murine models, the authors also found a positive correlation between the tumour hypoxic fraction and [ 18 F]FMISO uptake [231] . In a third publication, these investigators confirmed initial results from Chapman et al. [213] : the uptake inhibition in hypoxic cells is directly related to increased oxygen concentrations [232] . These three articles firmly established the relationship between [ 18 F]FMISO uptake and the hypoxic fraction in tumours. Further experiments aimed to quantify this relationship with a view to allowing reliable measurement of the hypoxic fraction based on the intensity of uptake, thereby contributing to planning and evaluation of radiation therapy in humans. Various mathematical approaches have been tested both in vitro and in animal models, with results that were consistent with the hypoxic fraction as measured using cell survival curves and oxygen consumption [233] [234] [235] . A more conventional approach used the SUV, and found a negative exponential relationship between liver SUVs in pigs and the oxygen pressure in this organ [228] . Whatever the method, however, [ 18 F]FMISO uptake measurements underestimate hypoxia in severe conditions (pO 2 ≤2-3 mmHg). This is probably related to the existence of a threshold below which bioreduction and cell uptake of [ 18 F]FMISO cease to increase [235] . This hypothesis is consistent with the negative exponential relationship existing between [ 18 F]FMISO uptake and tissue pO 2 , the threshold corresponding to the point at which the curve tends towards its asymptotes [236] .
Following the initial feasibility studies performed in humans by Koh et al. [237] and Valk et al. [238] , [ 18 F]FMISO has been used as a tracer for assessing myocardial ischaemia [239] and tumour hypoxia. Koh et al. first demonstrated fairly favourable uptake ratios between tumour and plasma, superior to 1.4 in six of eight patients before radiation therapy (and in all five with head and neck carcinoma). There was no uptake in the three patients who underwent a second PET study, after treatment [237] . The same year, Valk et al. visualised three gliomas with [ 18 F]FMISO and PET [238] . Further studies used [ 18 F]FMISO to demonstrate hypoxia in head and neck carcinomas and their lymph node metastases (with a lower efficiency in the latter case) [240] , nonsmall cell lung cancers [224] and soft tissue sarcomas [241] . Various methods have been proposed for quantification of uptake and thus hypoxia. Koh et al. [242] defined the hypoxic fraction volume (FHV) as the percentage of tumour pixels whose uptake was at least 1.4-fold higher than that of plasma, 120 min post injection. The authors showed a significant decrease in FHV after irradiation (from 58% before to 22% after treatment, median values) as well as the absence of any relationship between tumour volume and FHV before treatment. However, while one patient did not show any tumour uptake after treatment, the FHV remained unchanged in two other patients, suggesting that radiation therapy protocols should be adapted according to the level of hypoxia observed in each patient in order to limit the resistance to treatment. The same group confirmed these preliminary results in 37 patients with various malignant diseases, including 21 NSCLC and seven head and neck carcinomas. Ninety-seven percent of the tumours accumulated [ 18 F]FMISO, but with a high variability among tumour types and at different tumour sites in the same patient [224] . Such heterogeneity was also reported in comparative studies with both [ 18 F]FMISO and FDG in animals [243] and humans [241] . In 19 patients with soft tissue sarcomas, there was no relationship between FHV and VEGF expression, tumour grade or volume. In 10/19 patients who benefited from neo-adjuvant chemotherapy, the pixel by pixel correlation between [ 18 F]FMISO and FDG uptake was 0.46 and 0.32, before and after treatment, respectively, even though the uptake in most tumours decreased with both tracers after chemotherapy. This study underscores the value of using alternative tracers, and particularly [ 18 [214] and slightly modified by the Finnish investigators [244] . The synthesis is completed within 50 min, with a radiochemical purity superior to 95%, and 13-20% radiochemical yields (corrected for decay) and a specific activity in the range of 330 GBq/µmol [244] . In vivo studies using a rat mammary cancer model showed tumour/blood and tumour/muscle uptake ratios higher than those obtained with [ 18 F]FMISO [214] . There was significant liver and tumour uptake, and no binding to plasma proteins and no peripheral metabolism, which explains the primarily urinary excretion of the unmodified compound. The low uptake by fat, brain and bone tissues suggests good in vivo stability of the molecule and absence of defluorination [244] . The only human studies were performed in head and neck cancers [245] [246] [247] . They showed more favourable tumour/muscle uptake ratios than had been reported with [ 18 F]FMISO. The uptake was also more variable, however, related to the variations in tumour blood flow, as measured using [ 15 O]H 2 O and PET [245] .
Various methods have been tested for quantification of [ 18 F]FETNIM uptake, including dynamic analyses developed by Patlak and Blasberg [248] and Logan [249] , the SUV and the tumour/blood or tumour/muscle uptake ratios. Quantitative methods depended upon too many unverifiable parameters and were thus not validated, whereas the tumour/plasma uptake ratios provided the best estimates for tumour hypoxia [247] . The uptake ratios appear more favourable for [ 18 
which is used for measurement of hypoxia by immunohistochemistry [252] and flow cytometry [253] . EF5, like 2-nitroimidazole, binds to intracellular proteins following hypoxia-dependent bioreduction by cell nitroreductases. Taking advantage of the immunological properties of protein-EF5 conjugates, monoclonal antibodies such as ELK2-4 [215] and ELK3-51 [254] have been developed. More recently, a fluorinated analogue of EF5 was synthesised by electrophilic fluorination of 2-(2-nitro-1H-imidazol-1-yl)-N-(2,3,3-trifluoroallyl)-acetamide [255] . Both compounds, [ 18 F]EF1 and [ 18 F]EF5, have been studied in rats, using two tumour models, the hypoxic Morris 7777 or Q7 and the aerobic 9LF [256, 257] . Both tracers were excreted predominantly via the urinary tract, and only the hypoxic Q7 tumours were clearly visualised. The uptake was also directly related to the level of hypoxia, as measured using Eppendorf needles and immunohistochemistry. To date, no published data are available regarding these compounds in human studies. [258] should also be mentioned, even though these compounds are still at a very preliminary step of development.
Sodium fluoride: [ 18 F]NaF
The complex [ 18 [260] . In patients with secondary hyperparathyroidism, the [ 18 F]fluoride incorporation rate was correlated with the plasma parathormone level and with the bone formation rate [261] . In mice, [ 18 F]NaF-PET clearly identified fractures as foci of increased uptake at up to 7 weeks after the initial trauma, as well as human bone grafts in mice 2 months after the implantation and osteoblastic lesions induced by human prostate cancer cells (LAPC-9) [262] . Lytic lesions from human prostate cancer cells (CL-1 and PC-3) were visualised either as foci of globally increased activity or, more frequently, as rim-like foci, surrounding the edge of the lesions. Quantitative uptake, measured as cps/pixel per minute, was fairly reproducible in femoral and humeral regions of interest drawn on four studies over a period of 4 weeks. In patients with bone metastases from breast cancer, all lesions were visualised on PET as hot spots, whether they were osteolytic, osteoblastic or mixed on CT or MRI [263, 264] . However, there was no correlation between uptake intensity and bone density as measured with CT, with sometimes a very high [ 18 F]fluoride uptake localised in osteolytic areas. In the same study, foci of increased activity on bone scintigraphy using a Tc-labelled compound corresponded to foci on PET, but single-photon scintigraphy displayed limited spatial resolution and was also acquired in planar mode only, so that a lesion by lesion analysis was impossible. Schirrmeister et al. have shown higher diagnostic accuracy of [ 18 F]NaF-PET over both planar and SPECT scintigraphy for staging the skeleton in breast and non-small cell lung carcinoma [4, 265, 266] . In the most recent article, the difference in sensitivity was only significant for planar imaging (78% sensitivity), whereas SPECT (94%) and PET (99%) provided similar results, without any impact of the latter on patient management [267] . The exact role of [ 18 F]NaF-PET in the diagnostic armamentarium of bone metastases remains to be established, especially given the wide availability of less expensive techniques such as bone scintigraphy and SPECT, and the performance of MRI. An example of bone metastases is shown in Fig. 11 .
[ 18 F]-5-fluorouracil: 5-[ 18 F]FU
At the end of the 1950s, 5-fluorouracil (5-FU) was the first pyrimidine analogue proposed as an antitumour agent [268, 269] . Alone or in combination with other drugs, 5-FU has been used in various types of cancer, including colorectal, breast and head and neck. Several mechanisms explain the antitumour properties of 5-FU, but its toxicity stems from the incorporation of the phosphorylated form into nucleotides, in place of uracil. 5-FU belongs to the class of the antimetabolite agents, because its principal action is to inhibit the TS enzyme involved in the metabolism of nucleic acids. It is quickly catabolised in the liver into 5,6-dihydrouracil (FUH 2 ), an inactive derivative which is eliminated by the kidneys. [270] [271] [272] [273] [274] [275] . Various fluorinating agents have been proposed, with various purification methods [270, 271, [276] [277] [278] [279] , and the first automated and rapid synthesis was published in 1989 by Visser et al. [279] . The radiochemical yield was approximately 70%, and a 740 MBq (20 mCi) sample of 5-[ 18 F]FU was obtained with a specific activity of 37 GBq/µmol (1 Ci/µmol). More recently, similar results were obtained using a two-step protonic irradiation, in order to produce larger quantities of fluorine-18, and with the major advantage of producing lower amounts of non-labelled uracil during the synthesis [280] (Fig. 12) .
Biodistribution studies in rodents showed very rapid blood clearance (biological half-life 2 min), liver catabolism and both biliary and urinary excretion of fluorinated metabolites [281] . In tumour-bearing animals, 5-[ 18 F]FU was incorporated into tumour nucleotides, with a tumour uptake higher than that in the spleen, liver and small intestine [282] . Although preliminary studies suggested a relationship between 5-[ 18 F]FU uptake and tumour response to treatment in animal models [273] , further experiments failed to confirm such results [274, 275, 283] . Shani et al. showed that pretreatment with 5-FU influenced the elimination of 5-[ 18 F]FU, which suggests different catabolic pathways before and after treatment, capable of modifying the quantity of radiotracer available for the tumours [284] . It is possible to block the catabolism of 5-FU with eniluracil (5-ethynyluracil), which inactivates a key enzyme, dihydropyrimidine dehydrogenase [285] . Tumour SUVs and tumour to plasma, liver and kidney activity ratios were doubled using this method in tumour-bearing rats [286] . Also, Visser et al. demonstrated that the retention time of the tracer was longer in tumours responding to 5-FU than in nonresponding lesions [279, 287] .
Initial studies reported a very similar biodistribution in humans and rats [275, 283] . However, biliary excretion is somewhat more variable, with significant differences among patients [288] . 5-[ 18 F]FU has primarily been investigated in humans with the aim of predicting the response to chemotherapy with 5-FU. Dynamic studies have been performed in patients with liver metastases from colorectal cancer, using intra-arterial [289] or intravenous injection of the tracer [290] [291] [292] [293] . The group in Heidelberg has the largest experience in the field. They have shown that: (1) uptake by metastases is highly variable from one patient to another and, within a single patient, from one lesion to another [291] [292] [293] ; (2) most metastases show a low level of accumulation, so that lesions are faintly visualised as defects inside an otherwise highly tracer-avid liver parenchyma [291, 292] ; and (3) there is a positive correlation between 5-[ 18 F]FU uptake by the tumour at baseline and the subsequent response to treatment [292, 294] . Recent studies have investigated the effect of eniluracil on tracer uptake by liver metastases from colon cancer. Preliminary results obtained in small series indicated increased tumour uptake, with concomitant lower liver and renal uptake, resulting from the lower metabolisation of the tracer [295, 296] .
Obviously, since the scope of this review was so broad, difficult choices had to be made. In particular, tracers for gene expression were left aside, as we felt they would deserve a complete article. Other research avenues are being actively pursued, such as the development of fluorinated radiotracers for assessment of α(v)β3 integrin expression, which plays a major role in tumour growth and tumour-induced angiogenesis [297] [298] [299] .
Conclusion
The success of FDG as a general tracer for characterising and staging a wide variety of cancers has rejuvenated nuclear medicine and created new demands and opportunities. This should form the basis for efforts to capitalise on the future widespread availability of positron hybrid systems (PET/CT) and cyclotrons in order to consolidate and develop areas already covered by nuclear medicine using single-photon tracers. Such examples include substituting [ 18 F]NaF for diphosphonates for bone scanning and replacing 111 In or 99m Tc-labelled ligands by 18 F-labelled ligands for receptor scintigraphy. Fluorinated tracers need to be developed for indications in which FDG has proven unsuccessful or suboptimal, primarily the evaluation of frequent cancers such as prostate cancer or well-differentiated tumours. In addition, tracers offering improved specificity (differentiation between tumoural and inflammatory lesions) and tracers designed to permit effective monitoring of treatment response need to be sought. This review provides evidence that progress in meeting these goals is well underway, and that such advances will contribute to the growing success of PET.
